Otsuka Corporation (TYO:4768)
Japan · Delayed Price · Currency is JPY 3,092.00
+18.00 (0.59%)
Oct 24, 2025, 3:30 PM JST
Otsuka Revenue
Otsuka had revenue of 379.59B JPY in the quarter ending June 30, 2025, with 25.25% growth. This brings the company's revenue in the last twelve months to 1.23T, up 20.18% year-over-year. In the year 2024, Otsuka had annual revenue of 1.11T with 13.33% growth.
Revenue (ttm)
1.23T
Revenue Growth
+20.18%
P/S Ratio
0.95
Revenue / Employee
127.38M
Employees
9,680
Market Cap
1.17T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.11T | 130.30B | 13.33% |
| Dec 31, 2023 | 977.37B | 116.35B | 13.51% |
| Dec 31, 2022 | 861.02B | 9.13B | 1.07% |
| Dec 31, 2021 | 851.89B | 15.57B | 1.86% |
| Dec 31, 2020 | 836.32B | -50.21B | -5.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sony Group | 13.01T |
| Fujitsu | 3.54T |
| NEC Corporation | 3.45T |
| Tokyo Electron | 2.43T |
| TDK Corporation | 2.22T |
| Murata Manufacturing | 1.74T |
| Kioxia Holdings | 1.62T |
| Nintendo | 1.49T |
Otsuka News
- 3 months ago - Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting - Seeking Alpha
- 3 months ago - SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka - Benzinga
- 5 months ago - Vera plunges as Otsuka outperforms with IgA nephropathy therapy - Seeking Alpha
- 5 months ago - Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) - Benzinga
- 7 months ago - Arbitrum DAO mulls winding down unsustainable Web3 gaming fund - Cointelegraph
- 8 months ago - Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
- 9 months ago - Vera plunges as Otsuka updates on rival therapy - Seeking Alpha
- 11 months ago - Otsuka submits NDA in Japan for the treatment of hypercholesterolemia - Seeking Alpha